News
GNMSF
265.00
NaN%
--
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Barchart · 2d ago
Major Shareholder Announcement
Barchart · 3d ago
Bicara: Maintaining 'Buy' Rating On Ficerafusp Alfa Phase 3 Advancement
Seeking Alpha · 3d ago
Major Shareholder Announcement
Barchart · 4d ago
Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in Genmab
Barchart · 03/19 13:21
Passing of Genmab A/S’ Annual General Meeting
Barchart · 03/19 09:06
Completion of Share Buy-back Program
Barchart · 03/16 09:09
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Barchart · 03/02 13:58
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Barchart · 02/27 14:23
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
Barchart · 02/27 14:21
Genmab to Participate in Upcoming Investor Conferences
Barchart · 02/25 09:27
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Barchart · 02/24 14:20
Transactions in Connection with Share Buy-back Program
Barchart · 02/23 08:33
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Barchart · 02/20 09:05
Notice to Convene the Annual General Meeting of Genmab A/S
Barchart · 02/18 08:09
Genmab GAAP EPS of $15.37, revenue of $3.72B misses by $50M; initiates FY26 outlook
Seeking Alpha · 02/18 04:53
Genmab Announces Initiation of Share Buy-Back Program
Barchart · 02/17 14:14
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
Barchart · 02/17 10:23
Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance
Seeking Alpha · 01/30 03:30
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Barchart · 01/29 11:49
More
Webull provides a variety of real-time GNMSF stock news. You can receive the latest news about Genmab A/S through multiple platforms. This information may help you make smarter investment decisions.
About GNMSF
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.